Orbis Health Solutions (United States)

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale et al. · Annals of Surgical Oncology · 2021 · 38 citations · Full text

Medicine, Oncology, Surgery +17

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Garth S. Herbert, Timothy J. Vreeland, Guy T. Clifton et al. · Vaccine · 2018 · 24 citations

Medicine, Immunology, Oncology +17

Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

Elizabeth Lee Carpenter, Spencer Van Decar, Alexandra M. Adams et al. · Journal for ImmunoTherapy of Cancer · 2023 · 21 citations · Full text

Medicine, Immunology, Oncology +17

Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial

Alexandra M. Adams, Elizabeth L. Carpenter, Guy T. Clifton et al. · Cancer Immunology Immunotherapy · 2022 · 13 citations · Full text

Medicine, Immunology, Oncology +17

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

Robert C. Chick, Mark B. Faries, Diane F. Hale et al. · Cancer Medicine · 2021 · 12 citations · Full text

Medicine, Immunology, Oncology +17